Key points from article :
NADMED, a Helsinki-based biotech firm, has successfully secured €3.5 million in Series A funding to advance its cutting-edge technology for personalised medicine. The investment round was led by Nordic Science Investments (NSI), with contributions from previous backers Voima Ventures and the University of Helsinki Funds, along with additional European investors and a grant from Business Finland.
NADMED, founded in 2022, focuses on measuring crucial molecules called nicotinamide adenine dinucleotide (NAD) and glutathione, which are essential for energy production, cellular repair, and overall health. Imbalances in these molecules are linked to various age-related conditions, such as metabolic disorders, cancer, cardiovascular and neurological diseases, and muscle atrophy.
NADMED's technology, developed from research at Professor Anu Suomalainen Wartiovaara’s lab at the University of Helsinki, offers a novel approach to measuring all four NAD forms using a small blood sample with high precision.
This advancement allows for accurate, rapid testing of NAD and glutathione levels, which has become increasingly important as research connects these biomarkers to various health issues. The company's solution uses colorimetric quantification and provides a cost-effective, high-throughput alternative to traditional mass spectrometry methods.
The funding will enable NADMED to expand its operations into the US and other international markets, aiming to enhance personalised treatment options and improve diagnostics and therapy monitoring. CEO emphasised that metabolism will be a significant focus in medicine, and NADMED’s technology is poised to revolutionise personalised health and disease management. NSI’s investment supports NADMED’s mission to leverage its technology for better global health outcomes, tapping into a growing market with diverse opportunities.
